{"id":"tilidine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T17:02:00.574912","allNames":"tilidate","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Mu-type opioid receptor","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T02:17:27.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Pain","diseaseId":"pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(148)","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":546,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":355,"reaction":"DYSPNOEA"},{"count":337,"reaction":"FALL"},{"count":322,"reaction":"NAUSEA"},{"count":269,"reaction":"ANAEMIA"},{"count":245,"reaction":"DIZZINESS"},{"count":233,"reaction":"FATIGUE"},{"count":223,"reaction":"PAIN"},{"count":220,"reaction":"VOMITING"},{"count":205,"reaction":"DIARRHOEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":148,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul","pmid":"40562057","title":"[Basic knowledge of drug pain therapy in the palliative situation].","journal":"Deutsche medizinische Wochenschrift (1946)"},{"date":"2025 May 7","pmid":"40539377","title":"Effect of transversus abdominis plane blocks in abdominoplasties on postoperative outcomes.","journal":"BJS open"},{"date":"2025 Oct","pmid":"39636418","title":"[Opioid prescriptions for insured individuals without cancer in Germany: data from the BARMER].","journal":"Schmerz (Berlin, Germany)"},{"date":"2024 Sep 22","pmid":"39182980","title":"Studying drug excretion into exhaled breath aerosol - A workflow based on an impaction sampling device and LC-HRMS/MS analysis.","journal":"Analytica chimica acta"},{"date":"2024 Aug","pmid":"39135487","title":"Pain Medication and Pain Intensity Following Hip Fractures-Analyses Based on the ProFem Cohort Study.","journal":"Pharmacoepidemiology and drug safety"}],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Tilidate","genericName":"TILIDINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tilidate, also known as Tilidine, is a small molecule drug that targets the Mu-type opioid receptor. It is classified as a tilidine and is used to treat pain. The commercial status of Tilidate is unknown, but it is not FDA-approved. Key safety considerations include its potential for dependence and abuse. Tilidate has a half-life of 5.0 hours and a bioavailability of 90%.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}